News & Updates
Showing Infectious Diseases articles
Showing
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
During the surge of the Omicron (B.1.1.529) variant, antiviral therapy with nirmatrelvir significantly reduced the rate of COVID-19-related hospitalization or death among patients aged ≥65 years, according to a recent study.
3D-printed masks a good alternative to N95 respirators
Reusable 3D-printed respirators offer a cost-effective alternative to N95 masks in providing protection against respiratory pathogens, such as SARS-CoV-2, suggests a recent study. In addition, fit testing results show that some 3D-printed mask designs appear to exceed the fit of N95 masks.
COVID-19 lockdown weakens metabolism in people with glucose intolerance
In Japan, the declaration of a state of emergency in response to the COVID-19 pandemic led to negative metabolic consequences in people with glucose intolerance, such as lowered skeletal muscle and increased body weight and body fat, a recent study has found.
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.
Pandemic-fueled psych problems, fear of recurrence common among cancer patients
Psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, are common among cancer patients during the COVID-19 pandemic, as were fears of disease progression or recurrence, a recent study has found.
Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.